IRadimed Powers Ahead with Record Q2 Revenues, Eyes $100 Million Run Rate
IRadimed Corporation has announced a stellar performance in its second quarter of 2025, with revenues reaching $20.4 million - a 14% increase over the same period last year. This marks the company's 16th consecutive quarter of record revenues.
CEO Roger Susi attributed the success to strong demand for the MRidium 3860+ pump, which continued to excel in Q2. Additionally, shipments of the company's MR patient monitor grew 9%, with bookings indicating that sales targets for 2025 can be expected to be met.
Despite initial concerns about tariffs and their impact on components used by IRadimed, Susi noted that the actual effect has been minimal. The company is now better equipped to manage and report on tariff impacts in the future.
A significant development for the company was the FDA clearance of its new 3870 IV pump system for distribution. This clearance marks a major milestone for IRadimed, with Susi describing it as "seminal" and potentially leading to revenues exceeding $100 million by the end of 2026.
The CEO outlined the company's strategy for the coming quarters, including targeting an additional 1,000 channels per year in the US market through replacement sales of older pumps. This would bring the total number of annual replacements to 2,000 and beyond, further driving revenue growth.
Susi expressed pride in IRadimed's achievements, stating that even modest revenue targets from 20 years ago now seem overly conservative. As the company continues on its upward trajectory, investors and analysts alike will be watching with interest to see how IRadimed executes its plans and achieves its ambitious revenue projections.
